 Women diagnosed with minor atypia following a routine Pap smear will be randomised into one of the three management arms of the study a HPV DNA test, b Decision Aid DA with choice of management, or c a 6 month repeat Pap smear conventional management. Women who are allocated to the HPV DNA arm and the repeat Pap will receive standard information about their management strategy. Women allocated to the decision aid arm will receive information about HPV DNA testing and 6 month repeat Pap in a decision aid format as an adjunct to usual clinical care and asked to indicate their preference for management. Women in this arm will receive the management strategy of their choice HPV DNA or repeat Pap. The impact of the Decision Aid will be assessed and psychosocial impact of each management strategy will be followed up over the short, medium and long term. 